多发性硬化试验中非显著性主要结局的表述扭曲:Spin策略
结果显示62.5%的文献至少在一个部分存在spin,47.5%在三个或以上部分存在,且与较小样本量、非Q1期刊及第一作者 affiliation 不在欧美显著相关。
要点
- 62.5%的多发性硬化RCT在至少一个部分存在spin,47.5%在三个或以上部分存在。
- Spin最常见于摘要结论、讨论和结论部分。
- 较小样本量、非Q1期刊及第一作者 affiliation 不在欧美与spin显著相关。
核心结论
- 在报告非显著性主要结局的多发性硬化随机对照试验中,spin常见,可能误导临床决策。
主要发现
- Spin最常见于摘要结论、讨论和结论部分。
- Spin与较小样本量显著相关(OR=7.00,95%CI=1.29-37.91,p=0.024)。
- Spin与非Q1期刊显著相关(OR=4.38,95%CI=1.03-18.63,p=0.046)。
- Spin与第一作者 affiliation 不在欧洲或美国显著相关(OR=5.09,95%CI=1.15-22.62,p=0.032)。
临床怎么用
- 阅读多发性硬化RCT时,应警惕摘要结论、讨论和结论部分可能存在的spin,结合主要结局的统计学非显著性进行审慎解读。
局限性
- 本文为观察性系统评价,仅纳入报告非显著性主要结局的3期和4期平行优效性随机对照试验,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Spin refers to reporting strategies that highlight the benefits of an experimental treatment or divert attention from nonsignificant primary outcomes. To assess spin in randomized clinic trials (RCTs) on pharmaceutical efficacy in multiple sclerosis (MS) and explore associated factors. METHODS: A systematic literature search was conducted in MedLine (PubMed), EMBASE, and Cochrane using database-specific thesauri ("Multiple Sclerosis" and "Drug Therapy") to identify relevant studies. We included multiple sclerosis phase 3 and 4 randomized controlled trials with parallel, superiority designs that were published between 2013 and 2024 reporting nonsignificant primary outcomes. Spin was assessed in title, abstract conclusion, results, discussion, and conclusions. A descriptive analysis was followed by exploratory bivariate logistic regression. Independent variables included trial phase, sample size, drug type, comparison, follow-up time, registration, Consolidated Standards of Reporting Trials (CONSORT) mention, risk of bias (RoB2), journal quartile, first author affiliation, and conflict of interest. RESULTS: Forty articles met inclusion criteria. Spin appeared in at least one section in 25 articles (62.5%) and in 3 or more in 19 articles (47.5%). The most frequent locations were abstract conclusions, discussion, and conclusions. Spin was significantly associated with smaller sample size (odds ratio [OR] = 7.00, 95% confidence interval [CI] = 1.29-37.91, p = 0.024), non-Q1 journals (OR = 4.38, 95% CI = 1.03-18.63, p = 0.046), and first author affiliation outside Europe or the United States (OR = 5.09, 95% CI = 1.15-22.62, p = 0.032). INTERPRETATION: Spin is common in MS randomized controlled trials with nonsignificant primary outcomes and may mislead clinical decisions. ANN NEUROL 2026;99:316-327.
引用
- Mascareñas-García M, Rivero-de-Aguilar A, Candal-Pedreira C, et al. Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials. Ann Neurol. 2026. PMID: 41586489. doi:10.1002/ana.78125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。